Medical Packaging Films Market Outlook:
Medical Packaging Films Market size was over USD 8.81 billion in 2025 and is projected to reach USD 15.93 billion by 2035, growing at around 6.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of medical packaging films is evaluated at USD 9.29 billion.
The growth of the market can primarily be ascribed to the exponential growth in global health expenditures. Based on the statistics released by the World Bank, health expenditures across the globe reached approximately 1,121.9 U.S. dollars per capita in 2019. Further, the growth of the market can be attributed to the surging demand for bioplastic materials, and bi-axially oriented films for packaging pharmaceutical products to secure them from any kind of damage and contamination. The benefits of bioplastics are frequently touted as lower usage of fossil fuel resources, a lesser carbon footprint, and rapid decomposition. Bioplastic is also less hazardous, and it does not encompass bisphenol A (BPA), a hormone disruptor that is commonly found in regular plastics.
In addition to these, factors that are believed to fuel the growth of medical packaging films market include the rising proportion of patients who have been suffering from numerous types of chronic disorders throughout the world. For instance, in the United States, nearly half of all Americans, or around 138 million people, are projected to have at least one chronic disease, such as arthritis, heart disease, or hypertension. This number is nearly 16 million more than it was just ten years ago, and by 2030, it is estimated to rise to approximately 172 million. Additionally, medical packaging films market trends such as rising R&D on drug discovery and booming demand for medicines globally are also projected to influence the further growth of the market positively over the forecast period. Moreover, skyrocketing consumption of medicines and growing awareness toward the safety of medicines and drugs is further expected to hike the growth of the market over the forecast period. It is observed that the consumption of anti-hypertensive drugs in OECD countries rise by around 60% from 2000 to 2019. Hence, all these factors are anticipated to push the market growth further over the forecast period.
